• Corpus ID: 19562102

ive virus vaccines based on a yellow fever vaccine backbone : tandardized template with key considerations for a risk / benefit

  title={ive virus vaccines based on a yellow fever vaccine backbone : tandardized template with key considerations for a risk / benefit},
  author={P. Monatha and Stephen J. Seligmanb and James S. Robertsonc and runo Guyd and Edward B. Hayese and Richard Condit and Jean Louis Exclerg and Marie Maci and Baevin Carbery and Robert T. Cheni},
The Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG) was formed to evaluate the safety of live, recombinant viral vaccines incorporating genes from heterologous viruses inserted into the backbone of another virus (so-called “chimeric virus vaccines”). Many viral vector vaccines are in advanced clinical trials. The first such vaccine to be approved for marketing (to date in Australia, Thailand, Malaysia, and the Philippines) is a vaccine against the flavivirus, Japanese… 

Tables from this paper


ChimeriVax-West Nile Virus Live-Attenuated Vaccine: Preclinical Evaluation of Safety, Immunogenicity, and Efficacy
The safety, immunogenicity, and efficacy of the ChimeriVax-WN02 vaccine in the macaque model indicate the vaccine candidate is expected to be safe and immunogenic for humans.
Chimeric Yellow Fever Virus 17D-Japanese Encephalitis Virus Vaccine: Dose-Response Effectiveness and Extended Safety Testing in Rhesus Monkeys
ChimeriVax-JE meets preclinical safety and efficacy requirements for a human vaccine; it appears safer than yellow fever 17D vaccine but has a similar profile of immunogenicity and protective efficacy.
Safety of an attenuated West Nile virus vaccine, live Flavivirus chimera in horses.
These studies establish that this live attenuated Flavivirus chimera is safe to use for immunoprophylaxis against WNV disease in horses.
A live, attenuated recombinant West Nile virus vaccine.
  • T. Monath, Jian Liu, P. Bedford
  • Medicine, Biology
    Proceedings of the National Academy of Sciences of the United States of America
  • 2006
ChimeriVax-WN02 rapidly elicits strong immune responses after a single dose, and is a promising candidate warranting further evaluation for prevention of WN disease.
Substitution of wild-type yellow fever Asibi sequences for 17D vaccine sequences in ChimeriVax-dengue 4 does not enhance infection of Aedes aegypti mosquitoes.
In light of the low-level viremias that have been observed after vaccination in human volunteers coupled with low mosquito infectivity, it is predicted that the risk of mosquito infection and transmission of ChimeriVax vaccine recombinant/revertant viruses in nature is minimal.
Preclinical and Clinical Development of a YFV 17 D-Based Chimeric Vaccine against West Nile Virus
The construction, pre-clinical and clinical characterization of ChimeriVax-WN02 for humans, a live chimeric vaccine composed of a yellow fever 17D virus in which the prM-E envelope protein genes are replaced with the corresponding genes of the WN NY99 virus, and safety, viremia and immunogenicity were assessed.